GSK Just Sold a Drug Two Days Before the FDA Said Yes

Alfasigma isn't just buying a drug. They're buying a franchise.

The Itch Nobody Could Fix

To understand why this deal matters, you need to understand what PBC itch actually is. It's not a mosquito bite. It's not dry skin. It's a relentless, whole-body sensation that can make patients claw at their skin until it bleeds, keep them awake for hours, and erode their quality of life in ways that are hard to quantify but impossible to ignore.

Before Lynavoy, there was no FDA-approved treatment specifically for PBC-related itch. Patients could take ursodeoxycholic acid (UDCA), the standard therapy for the underlying liver disease, but about a quarter of diagnosed patients don't even receive any PBC treatment at all. And UDCA doesn't reliably fix the itching.

Linerixibat works differently. It's an IBAT inhibitor, which means it blocks a transporter in the gut that recycles bile acids. In PBC, excess bile acids are thought to trigger the intense itching. By preventing their reabsorption, the drug reduces the bile acid pool and, with it, the itch. Think of it as turning off the faucet instead of constantly mopping the floor.

The Trial That Sealed It

The approval rested on GLISTEN, a phase 3 trial conducted across 19 countries with 238 patients. Half received linerixibat; half got placebo. Both groups could continue their existing anti-itch medications.

The results were clear. Over 24 weeks, patients on linerixibat experienced a statistically significant reduction in their worst itch scores compared to placebo (p=0.001). Improvement showed up as early as week two, which matters enormously when your patients haven't slept properly in months. Sleep interference scores improved significantly too (p=0.024).

By week 24, 56% of patients on linerixibat achieved a meaningful three-point drop in their itch scores, compared to 43% on placebo. The most common side effect was mild diarrhea, consistent with how the drug works; only 4% of patients on linerixibat discontinued because of it, versus less than 1% on placebo.

For a drug targeting an orphan indication (one with relatively few patients), these numbers are compelling. Not blockbuster-drug dramatic, but real, measurable relief for people who had nothing.

A Small Market With Big Implications

PBC is rare, but it's getting less rare. U.S. prevalence nearly doubled between 2006 and 2021, climbing from about 22 per 100,000 to 41 per 100,000 people. North America has the highest prevalence globally, followed by Europe and the Asia-Pacific region.

The disease overwhelmingly affects women, at a ratio of roughly 4-to-1 over men. It typically strikes between the ages of 40 and 60, and many patients are diagnosed only incidentally through routine blood work.

Regulatory reviews are still underway in the EU, UK, Canada, and China. Linerixibat holds orphan drug designation in the U.S., EU, and Japan, plus priority review status in China. Each approval would expand Alfasigma's addressable market and could trigger additional milestone payments to GSK.

For the rare disease world, this deal signals something important: niche indications with genuine unmet need can still command serious money. A $300 million upfront payment for a drug in a market of ~100,000 U.S. patients is a strong statement. It tells other pharma companies that rare liver diseases aren't too small to chase.

The Scorecard

GSK walks away with $300 million in hand, $100 million more already triggered, and a royalty stream that could keep paying for years. They get to refocus on the big liver diseases that align with their long-term strategy.

Alfasigma gets the first (and currently only) FDA-approved therapy for PBC itch, a global regulatory pipeline with multiple decisions pending, and a cornerstone asset for their rare hepatology platform.

And patients with PBC? For the first time, they have an approved drug for the symptom that torments them most. Sometimes the best deals are the ones where everybody wins.